Table of Content

1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Artificial Intelligence in Digital Pathology
3.3. Workflow of AI-based Digital Pathology
3.4. Applications of AI-based Digital Pathology Solutions
3.5. Regulatory Requirements Focused on AI-based Digital Pathology:
3.6. Challenges Associated with the Use of AI in Digital Pathology
3.7. Future Perspectives

4. AI-BASED DIGITAL PATHOLOGY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AI-based Digital Pathology Providers: Overall Market Landscape
4.2.1. Analysis by Type of Product
4.2.2. Analysis by Type of Service Offered
4.2.3. Analysis by Type of Feature
4.2.4. Analysis by Additional Features
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Assay
4.2.7. Analysis by Area of Application
4.2.8. Analysis by Type of End-user
4.2.9. Analysis by Number of Available Software
4.3. AI-based Digital Pathology Providers: Developer Landscape
4.3.1. Analysis by Geographical Reach
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Company Size
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Location of Headquarters (Continent-wise)

5. AI-BASED DIGITAL PATHOLOGY MARKET: KEY INSIGHTS
5.1. Chapter Overview
5.1.1. Analysis by Type of Service and Area of Application
5.1.2. Analysis by Type of Feature and Area of Application
5.1.3. Analysis by Type of Product and Area of Application
5.1.4. Analysis by Type of Product and Location of Headquarters
5.1.5. Analysis by Company Size and Location of Headquarters

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. PathAI
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. Paige
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook
6.4. Akoya Biosciences
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook
6.5. PROSCIA
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook
6.6. Visiopharm
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook
6.7. Roche Tissue Diagnostics
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook
6.8. Aiforia Technologies
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook
6.9. Indica Labs
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook
6.10. Ibex Medical Analytics
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Benchmarking of Portfolio Strength
7.5. Benchmarking of Funding Strength
7.6. Company Competitiveness Analysis: Small Players
7.7. Company Competitiveness Analysis: Mid-sized Players
7.8. Company Competitiveness Analysis: Large Players

8. FUNDING AND INVESTMENTS
8.1. Chapter Overview
8.2. Types of Funding
8.3. AI-based Digital Pathology: List of Funding and Investments
8.3.1. Cumulative Year-wise Trend by Number of Instances
8.3.2. Cumulative Year-wise Trend by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Funding and Amount Invested
8.3.5. Analysis by Area of Application
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount Raised
8.4. Concluding Remarks

9. DEMAND ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Global Demand for AI-based Digital Pathology, 2022-2035
9.4. Demand for AI-based Digital Pathology: Analysis by Geography
9.4.1. Demand for AI-based Digital Pathology in North America
9.4.1.1 Demand for AI-based Digital Pathology in the US
9.4.1.2 Demand for AI-based Digital Pathology in Canada
9.4.2. Demand for AI-based Digital Pathology in Europe
9.4.2.1. Demand for AI-based Digital Pathology in UK
9.4.2.2. Demand for AI-based Digital Pathology in Germany
9.4.2.3. Demand for AI-based Digital Pathology in Spain
9.4.2.4. Demand for AI-based Digital Pathology in Italy
9.4.2.5. Demand for AI-based Digital Pathology in France
9.4.3. Demand for AI-based Digital Pathology in Asia
9.4.3.1. Demand for AI-based Digital Pathology in China
9.4.3.2. Demand for AI-based Digital Pathology in Japan
9.4.3.3. Demand for AI-based Digital Pathology in South Korea
9.4.4. Demand for AI-based Digital Pathology in Latin America
9.4.4.1. Demand for AI-based Digital Pathology in Brazil
9.4.5. Demand for AI-based Digital Pathology in MENA
9.4.5.1. Demand for AI-based Digital Pathology in Saudi Arabia
9.4.6. Demand for AI-based Digital Pathology in Rest of the World
9.4.6.1. Demand for AI-based Digital Pathology in Australia
9.5. Demand for AI-based Digital Pathology: Analysis by Type of End-user
9.5.1 Demand for AI-based Digital Pathology in Hospitals
9.5.2. Demand for AI-based Digital Pathology in Research Institutes
9.5.3. Demand for AI-based Digital Pathology in Other End-users
9.6. Concluding Remarks

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global AI-based Digital Pathology Market, 2022-2035
10.4. AI-based Digital Pathology Market: Analysis by Type of Neural Network, 2022 and 2035
10.4.1. AI-based Digital Pathology Market for Artificial Neural Network, 2022-2035
10.4.2. AI-based Digital Pathology Market for Convolutional Neural Network, 2022-2035
10.4.3. AI-based Digital Pathology Market for Fully Convolutional Network, 2022-2035
10.4.4. AI-based Digital Pathology Market for Recurrent Neural Network, 2022 – 2035
10.4.5. AI-based Digital Pathology Market for Other Neural Networks, 2022 – 2035
10.5. AI-based Digital Pathology Market: Analysis by Type of Assay, 2022 and 2035
10.5.1. AI-based Digital Pathology Market for ER Assay, 2022-2035
10.5.2. AI-based Digital Pathology Market for HER2 Assay, 2022-2035
10.5.3. AI-based Digital Pathology Market for Ki67 Assay, 2022-2035
10.5.4. AI-based Digital Pathology Market for PD-L1 Assay, 2022-2035
10.5.5. AI-based Digital Pathology Market for PR Assay, 2022-2035
10.5.6. AI-based Digital Pathology Market for Other Type of Assays, 2022-2035
10.6. AI-based Digital Pathology Market: Analysis by Type of End-user, 2022 and 2035
10.6.1. AI-based Digital Pathology Market for Academic Institutions, 2022-2035
10.6.2. AI-based Digital Pathology Market for Hospitals / Healthcare Institutions, 2022-2035
10.6.3. AI-based Digital Pathology Market for Laboratories / Diagnostic Institutions, 2022-2035
10.6.4. AI-based Digital Pathology Market for Research Institutes, 2022-2035
10.6.5. AI-based Digital Pathology Market for Other End-users, 2022-2035
10.7. AI-based Digital Pathology Market: Analysis by Area of Application, 2022 and 2035
10.7.1. AI-based Digital Pathology Market for Diagnostics, 2022-2035
10.7.2. AI-based Digital Pathology Market for Research, 2022-2035
10.7.3. AI-based Digital Pathology Market for Other Areas of Application, 2022-2035
10.8. AI-based Digital Pathology Market: Analysis by Target Disease Indication, 2022 and 2035
10.8.1. AI-based Digital Pathology Market for Breast Cancer, 2022-2035
10.8.2. AI-based Digital Pathology Market for Colorectal Cancer, 2022-2035
10.8.3. AI-based Digital Pathology Market for Cervical Cancer, 2022-2035
10.8.4. AI-based Digital Pathology Market for Gastrointestinal Cancer, 2022-2035
10.8.5. AI-based Digital Pathology Market for Lung Cancer, 2022-2035
10.8.6. AI-based Digital Pathology Market for Prostate Cancer, 2022-2035
10.8.7. AI-based Digital Pathology Market for Other Indications, 2022-2035
10.9. AI-based Digital Pathology Market: Analysis by Key Geographies, 2022 and 2035
10.9.1. AI-based Digital Pathology Market in North America, 2022-2035
10.9.1.1. AI-based Digital Pathology Market in the US, 2022-2035
10.9.1.2. AI-based Digital Pathology Market in Canada, 2022-2035
10.9.2. AI-based Digital Pathology Market in Europe, 2022-2035
10.9.2.1. AI-based Digital Pathology Market in UK, 2022-2035
10.9.2.2. AI-based Digital Pathology Market in Germany, 2022-2035
10.9.2.3. AI-based Digital Pathology Market in Spain, 2022-2035
10.9.2.4. AI-based Digital Pathology Market in Italy, 2022-2035
10.9.2.5. AI-based Digital Pathology Market in France, 2022-2035
10.9.3. AI-based Digital Pathology Market in Asia, 2022-2035
10.9.3.1. AI-based Digital Pathology Market in China, 2022-2035
10.9.3.2. AI-based Digital Pathology Market in Japan, 2022-2035
10.9.3.3. AI-based Digital Pathology Market in South Korea, 2022-2035
10.9.4. AI-based Digital Pathology Market in Latin America, 2022-2035
10.9.4.1. AI-based Digital Pathology Market in Brazil, 2022 – 2035
10.9.5. AI-based Digital Pathology Market in MENA, 2022-2035
10.9.5.1. AI-based Digital Pathology Market in Saudi Arabia, 2022-2035
10.9.6. AI-based Digital Pathology Market in Rest of the World, 2022-2035
10.9.6.1. AI-based Digital Pathology Market in Australia, 2022-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. aetherAI
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Joe Yeh (Chief Executive Officer and Chairman)
12.3. CTL Clinitech Lab
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Suraj Bramhane (Laboratory Director and Chief Pathologist)
12.4. Huron Digital Pathology
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Savvas Damaskinos (Vice President, Research and Technology)
12.5. Mindpeak
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Anil Berger (Vice President, Sales and Marketing)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION